Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET
Cabozantinib achieved 86% response rates as first-line treatment for brain tumors from kidney cancer, offering durable disease control.
The CABRAMET trial is the first prospective evaluation of cabozantinib for untreated brain metastases in renal cell carcinoma, showing a 61.5% brain response rate and durable responses. First-line efficacy was particularly striking at 86% response rate.
What the study was
- Study design
- Multicenter phase II, open-label, single-arm
- Population
- RCC patients with non-locally pretreated brain metastases
- Sample size
- 26
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- European Journal of Cancer
Why it surfaced
First prospective trial of cabozantinib for RCC brain metastases showing impressive durable responses, addresses a major unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.